GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been selected for poster presentation in a poster discussion session at the 2025 ATS International Conference being held May 18-21, 2025 in San Francisco, CA.

Details of the presentation are as follows:

Title: Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis
Poster Board Number: 810
Presenter: Marc Hertz, PhD, Chief Executive Officer of GRI Bio
Session: D21 - IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR
Date and Time: Wednesday, May 21, 2025 from 8:15-10:15 AM PT
Location: Room 2022/2024 (West Building, Level 2), Moscone Center

For more information about the 2025 ATS International Conference, please visit the conference website, here.

Read more at globenewswire.com